Scale-up of a temporary bioartificial liver support system described in BioResearch Open Access

December 19, 2012

New Rochelle, NY, December 19, 2012--Acute liver failure is usually fatal without a liver transplant, but the liver can regenerate and recover if given time to heal. A bioartificial liver machine that can provide temporary support while organ regeneration takes place has been scaled up for testing in a large animal model and is described in an article in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available on the BioResearch Open Access website .

A team of researchers from University College London (UCL), UCL Medical School, and University of Cambridge in the U.K., and Université de Technologie de Compiègne, France, developed a method in which they encapsulated human-derived liver cells in alginate and allowed them to grow and multiply in a bioreactor. Eloy Erro and colleagues optimized the growth conditions and nutrient and oxygen levels so the encapsulated liver cells in the bioreactor could reach a density sufficient to support a human liver. The authors describe their methods and the storage protocol they devised for transporting the bioartificial liver machine from the laboratory to a patient's bedside within 48 hours in the article, "Bioengineering the Liver: Scale Up and Cool Chain Delivery of the Liver Cell Biomass for Clinical Targeting in a Bioartificial Liver Support System."

"As the demand for liver transplantation exceeds the supply, there is a real need to pursue more innovative approaches to solve this problem," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland. "The article described here demonstrates a significant step towards achieving this goal."
-end-
About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including ASSAY and Drug Development Technologies, Tissue Engineering, Stem Cells and Development, Human Gene Therapy, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website. Mary Ann Liebert, Inc.
140 Huguenot St.
New Rochelle, NY 10801-5215
www.liebertpub.com
Phone: 914-740-2100
800-M-LIEBERT
Fax: 914 740-2101

Mary Ann Liebert, Inc./Genetic Engineering News

Related Liver Transplant Articles from Brightsurf:

Advanced liver disease patients and transplant recipients need specific care during COVID-19
The European Association for the Study of the Liver (EASL) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) have issued a Position Paper, providing recommendations for clinicians caring for patients with liver diseases during the current pandemic.

Certain liver cells may help prevent organ rejection after transplant, study finds
Mesenchymal stromal cells from fat tissue and bone marrow are widely used in therapeutic trials for their anti-inflammatory qualities, but new Mayo Clinic research finds that liver cells may be of greater value.

University of Cincinnati finds new option for liver transplant patients
Budesonide, a drug commonly used to treat Crohn's Disease, may offer fewer side effects and work at least as well as prednisone as an anti-organ rejection medication in liver transplant patients.

Cleveland clinic's first purely laparoscopic living donor surgery for liver transplant
Cleveland Clinic has successfully performed the Midwest's first purely laparoscopic living donor surgery for liver transplantation in an adult recipient.

Alcohol relapse rate among liver transplant recipients identical regardless of sobriety period
For decades, patients with liver disease related to alcohol use have been told they must be sober for six months before they can get a liver transplant.

Why liver transplant waitlists might misclassify high-risk patients
A new study in the journal Gastroenterology reveals that the standard method for ranking patients on the waitlist for lifesaving liver transplantation may not prioritize some of the sickest candidates for the top of the list.

Liver transplant for alcohol-related liver disease in US
The proportion of liver transplants in the United States for alcohol-associated liver disease increased between 2002 and 2016, with much of the increase associated with a decrease in liver transplant for hepatitis C virus infection because of antiviral therapy.

African-Americans may live longer after liver transplant if their donors are the same race
African-American adults undergoing liver transplant to treat liver cancer lived significantly longer if their organ donor was also African-American.

Liver transplant survival rate sees improvement among older adults
To learn more about older adults and liver transplants, a team of researchers studied information recorded by the Scientific Registry of Transplant Recipients (SRTR) from 2003 to 2016.

Anticancer drug offers potential alternative to transplant for patients with liver failure
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

Read More: Liver Transplant News and Liver Transplant Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.